PE20141527A1 - Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos - Google Patents

Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos

Info

Publication number
PE20141527A1
PE20141527A1 PE2013002448A PE2013002448A PE20141527A1 PE 20141527 A1 PE20141527 A1 PE 20141527A1 PE 2013002448 A PE2013002448 A PE 2013002448A PE 2013002448 A PE2013002448 A PE 2013002448A PE 20141527 A1 PE20141527 A1 PE 20141527A1
Authority
PE
Peru
Prior art keywords
same
ona
imidazol
amino
preparation
Prior art date
Application number
PE2013002448A
Other languages
English (en)
Inventor
Alain Braun
Olivier Duclos
Gilbert Lassalle
Franz Lorge
Valerie Martin
Aurelie Strub
Olaf Ritzeler
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44247865&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141527(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20141527A1 publication Critical patent/PE20141527A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) EN DONDE: W ES H O CH; Y ES ALQUINILENO C2-C3, 1,4-FENILENO OPCIONALMENTE SUSTITUIDO CON R7, QUE REPRESENTA UNO O MAS ATOMOS DE HALOGENO; Z ES UN ENLACE O UN GRUPO CR1R2, DONDE R1 Y R2 SON INDEPENDIENTEMENTE H, ALQUILO C1-C6, TRIFLUOROMETILO, ARILO, ENTRE OTROS; R3 ES H; R4 ES ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; R5 ES H O ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: 2-AMINO-1-ETIL-7-((3R)-3-HIDROXI-4-METOXI-3-METIL-BUT-1-INIL)-3-(1H-IMIDAZOL-2-IL)-1H-[1,8]NAFTIRIDIN-4-ONA; 2-AMINO-1-ETIL-7-[(1-HIDROXICICLOPENTIL)ETINIL]-3-(1H-IMIDAZOL-2-IL)-1H-[1,8]NAFTIRIDIN-4-ONA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION, A UNA COMPOSICION FARMACEUTICA Y A UNA COMBINACION
PE2013002448A 2011-05-20 2012-05-16 Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos PE20141527A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305624A EP2524915A1 (en) 2011-05-20 2011-05-20 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20141527A1 true PE20141527A1 (es) 2014-11-08

Family

ID=44247865

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002448A PE20141527A1 (es) 2011-05-20 2012-05-16 Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos

Country Status (35)

Country Link
US (2) US9126972B2 (es)
EP (2) EP2524915A1 (es)
JP (1) JP5937201B2 (es)
KR (1) KR102005121B1 (es)
CN (1) CN103687852B (es)
AR (1) AR086451A1 (es)
AU (1) AU2012261077B2 (es)
BR (1) BR112013029820B1 (es)
CA (1) CA2833192C (es)
CL (1) CL2013003091A1 (es)
CO (1) CO6811857A2 (es)
CR (1) CR20130541A (es)
CY (1) CY1116720T1 (es)
DK (1) DK2709996T3 (es)
DO (1) DOP2013000241A (es)
EA (1) EA023580B1 (es)
EC (1) ECSP13013016A (es)
ES (1) ES2548266T3 (es)
GT (1) GT201300250A (es)
HR (1) HRP20150974T1 (es)
HU (1) HUE025111T2 (es)
IL (1) IL229210A0 (es)
MA (1) MA35196B1 (es)
MX (1) MX348842B (es)
NI (1) NI201300125A (es)
PE (1) PE20141527A1 (es)
PL (1) PL2709996T3 (es)
PT (1) PT2709996E (es)
SG (1) SG194204A1 (es)
SI (1) SI2709996T1 (es)
TN (1) TN2013000420A1 (es)
TW (1) TWI532740B (es)
UA (1) UA109942C2 (es)
UY (1) UY34082A (es)
WO (1) WO2012159959A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
MA37821A1 (fr) * 2012-07-17 2018-02-28 Sanofi Sa Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CN111770934A (zh) * 2018-01-31 2020-10-13 赛诺菲 修饰的脂化松弛素b链肽及其治疗用途
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CN1191252C (zh) * 2003-08-11 2005-03-02 中国药科大学 3－位取代的喹诺酮衍生物及其在药学上的应用
JP4724665B2 (ja) * 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
KR100744826B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 이미다졸기가 치환된 퀴놀리논 유도체
WO2008121687A2 (en) 2007-03-28 2008-10-09 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
MA37821A1 (fr) * 2012-07-17 2018-02-28 Sanofi Sa Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire

Also Published As

Publication number Publication date
MA35196B1 (fr) 2014-06-02
JP2014513707A (ja) 2014-06-05
US9675606B2 (en) 2017-06-13
BR112013029820A2 (pt) 2016-12-06
CA2833192A1 (en) 2012-11-29
KR20140025465A (ko) 2014-03-04
MX2013013572A (es) 2014-01-16
JP5937201B2 (ja) 2016-06-22
CN103687852B (zh) 2016-08-17
WO2012159959A1 (en) 2012-11-29
CA2833192C (en) 2019-10-22
ES2548266T3 (es) 2015-10-15
US9126972B2 (en) 2015-09-08
TWI532740B (zh) 2016-05-11
EP2709996A1 (en) 2014-03-26
SI2709996T1 (sl) 2015-10-30
EA023580B1 (ru) 2016-06-30
AU2012261077A1 (en) 2013-12-12
US20140094488A1 (en) 2014-04-03
KR102005121B1 (ko) 2019-07-29
ECSP13013016A (es) 2013-12-31
EP2709996B1 (en) 2015-06-24
NI201300125A (es) 2014-02-20
PL2709996T3 (pl) 2015-12-31
UY34082A (es) 2013-01-03
NZ617931A (en) 2015-05-29
EA201391744A1 (ru) 2014-03-31
CO6811857A2 (es) 2013-12-16
DOP2013000241A (es) 2013-12-31
HRP20150974T1 (en) 2015-10-09
CN103687852A (zh) 2014-03-26
MX348842B (es) 2017-06-30
CY1116720T1 (el) 2017-03-15
HUE025111T2 (en) 2016-02-29
TN2013000420A1 (en) 2015-03-30
EP2524915A1 (en) 2012-11-21
US20150328205A1 (en) 2015-11-19
CL2013003091A1 (es) 2014-04-04
AR086451A1 (es) 2013-12-11
PT2709996E (pt) 2015-10-16
TW201300386A (zh) 2013-01-01
BR112013029820B1 (pt) 2020-02-04
SG194204A1 (en) 2013-12-30
GT201300250A (es) 2015-03-05
DK2709996T3 (en) 2015-09-28
AU2012261077B2 (en) 2016-05-05
CR20130541A (es) 2013-12-09
UA109942C2 (ru) 2015-10-26
IL229210A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
PE20180462A1 (es) Moduladores cot y metodos de uso de los mismos
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
PE20141527A1 (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos
AR078408A1 (es) Derivados de indol como moduladores de los crac
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
PE20142366A1 (es) Compuestos triazolo como inhibidores de pde 10
EA201171062A1 (ru) Алкиламидные соединения и их применение
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
AR051796A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas

Legal Events

Date Code Title Description
FD Application declared void or lapsed